Trial Profile
Multicentre, Prospective, Randomised, 2-arm Study to Assess the Impact of Ferric Carboxymaltose on Exercise Capacity in Chronic Heart Failure Patients With Iron Deficiency
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Chronic heart failure; Iron deficiency anaemia
- Focus Therapeutic Use
- Acronyms EFFECT-HF
- Sponsors Vifor Pharma
- 12 Jul 2017 Results published in the Circulation
- 07 Dec 2016 Results presented at the the American Heart Association's Scientific Sessions 2016, according to a Vifor Pharma media release.
- 07 Dec 2016 Results published in a Vifor Pharma media release.